Fludarabine plus cyclophosphamide and rituximab in waldenstrom macroglobulinemia: An effective but myelosuppressive regimen to be offered to patients with advanced disease

Cancer

Volumn 118, Issue 2, 2012, Pages 434-443

  Tedeschi, Alessandra ^a   Benevolo, Giulia ^b   Varettoni, Marzia ^c   Battista, Marta L ^d   Zinzani, Pier L ^e   Visco, Carlo ^f   Meneghini, Vittorio ^g   Pioltelli, Pietro ^h   Sacchi, Stefano ⁱ   Ricci, Francesca ^a   Nichelatti, Michele ^a   Zaja, Francesco ^d   Lazzarino, Mario ^c   Vitolo, Umbero ^b   Morra, Enrica ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f SAN BORTOLO HOSPITAL   (Italy)

^g UNIVERSITY OF VERONA   (Italy)

^h SAN GERARDO HOSPITAL   (Italy)

ⁱ UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Cyclophosphamide; Fludarabine; Immunochemotherapy; Purine analogs; Rituximab; Waldenstrom macroglobulinemia

Indexed keywords

BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; BILIARY COLIC; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CYTOPENIA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FAINTNESS; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEMOLYSIS; HEMOLYTIC ANEMIA; HERPES ZOSTER; HUMAN; HYPOTENSION; INFECTION; LIVER DISEASE; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUTROPENIA; NONHODGKIN LYMPHOMA; PEMPHIGUS VULGARIS; PNEUMONIA; POLYURIA; PRIORITY JOURNAL; RASH; REMISSION; SEPSIS; THROMBOCYTOPENIA; URINARY TRACT INFECTION; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSION; MALE; MIDDLE AGED; VIDARABINE; WALDENSTROM MACROGLOBULINEMIA;

EID: 84855489471     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26303     Document Type: Article

References (43)

1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30:110-115.
2. Dimopoulos MA, O'Brien S, Kantarjian H, et al. Fludarabine therapy in Waldenstrom's macroglobulinemia. Am J Med. 1993;95:49-52. (Pubitemid 23205926)
3. Leblond V, Ben-Othman T, Deconinck E, et al. Activity of fludarabine in previously treated Waldestrom's macroglobulinemia: a report of 71 cases. Group Cooperatif Macroglobulinemie. J Clin Oncol. 1998;16:2060-2064. (Pubitemid 28265041)
4. Leblond V, Levy V, Maloisel F, et al. Multicenter randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin- prednisone in 92 patients with Waldenstrom's macroglobulinemia in first remission or in primary refractory disease. Blood. 2001;98:2640-2644.
5. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenstrom's macroglobulinemia: results of United States intergroup trial (South West Oncology Group S9003). Blood. 2001;98:41-48.
6. Dhodapkar MV, Jacobson JL, Gertz MA, Crowley JJ, Barlogie B. Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SWOG 5903). Semin Oncol. 2003;30:220-225. (Pubitemid 36506313)
7. Dimopoulos MA, Hamilos G, Efstathiou E, et al. Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk Lymphoma. 2003;44:993-996. (Pubitemid 36416998)
8. Tam CS, Wolf MM, Westerman D, Januszewicz EH, Prince HM, Seymour JF. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma. 2005;6:136-139.
9. Tamburini J, Levy V, Chaleteix C, et al. Fludarabine plus cyclophosphamide in Waldenstrom's macroglobulinemia: results in 49 patients. Leukemia. 2005;19:1831-1834. (Pubitemid 41486163)
10. Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:243-247. (Pubitemid 36506318)
11. Byrd JC, White CA, Link B, et al. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol. 1999;10:1525-1527. (Pubitemid 30017067)
12. Foran JM, Rohatiner AZ, Cunningham D, et al. European II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle cell lymphoma, immunocytoma and small B-cell lymphoma. J Clin Oncol. 2000;18:317-324. (Pubitemid 30056420)
13. Treon SP, Agus DB, Link B, et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J Immunother. 2001;24:272-279. (Pubitemid 32479719)
14. Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR. Multicenter phase II trial of Waldenstrom's macroglobulinemia (WM): an Eastern Cooperative Oncology Group study (E3A98). Leuk Lymphoma. 2004;45:2047-2055. (Pubitemid 39232853)
15. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol. 2002;20:2327-2330.
16. Treon SP, Emmanouilides C, Kimby E, et al. Extended rituximab therapy in Waldenstrom's macroglobulinemia. Ann Oncol. 2005;16:132-138. (Pubitemid 40124490)
17. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B-cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm. 1997;12:177-186. (Pubitemid 27349961)
18. Alas S, Bonavida B, Emmanouilides C. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab. Anticancer Res. 2000;20:2961-2966.
19. Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Hematol. 2001;114:800-809. (Pubitemid 32953735)
20. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95:3900-3908. (Pubitemid 30412866)
21. Treon SP, Branagan AR, Ioakimidis L, et al. Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood. 2009;113:3673-3678.
22. Hensel M, Villalobos M, Kornacker M, Krasniqi F, Ho AD. Pentostatin, cyclophosphamide and rituximab an effective regimen for patients with Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma. 2005;2:131-135.
23. Laszlo D, Andreola G, Rigacci L, et al. Rituximab and subcutaneous 2-chloro-20-deoxyadenosine (2-CdA) combination treatment for patients with Waldenstrom's macroglobulinemia: clinical and biologic results of a phase II multicenter study. J Clin Oncol. 2010;13:2233-2237.
24. Tam CS, Wolf M, Prince HM, et al. Fludarabine, cyclophosphamide and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non Hodgkin lymphoma. Cancer. 2006;106:2412-2420. (Pubitemid 43791961)
25. Leblond V, Compain L, Levy V, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom's macroglobulinemia: results in 55 patients [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116. Abstract 1757.
26. Tedeschi A, Miqueleiz S, Ricci F, et al. Fludarabine, cyclophosphamide and rituximab in Waldenstrom's macroglobulinemia an effective regimen requiring a new category response criteria and a delayed assessment results [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110. Abstract 1290.
27. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30:116-120.
28. Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma. 2006;6:380-383.
29. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom's macroglobulinemia with dexamethasone rituximab and cyclophosphamide. J Clin Oncol. 2007;22:3344-3349. (Pubitemid 47325621)
30. Treon SP, Hunter Z, Branagan AR. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia. Clin Lymphoma. 2005;5:273-277. (Pubitemid 40614242)
31. Ioakimidis L, Patterson CJ, Hunter ZR, et al. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma. 2009;9:62-66.
32. Rummel MJ, von Gruenhagen U, Niederle N, et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with Waldenstrom's macroglobulinemia: first interim results of a randomized phase III study of the Study Group Indolent Lymphomas (StiL). Paper presented at: Fifth International Workshop on Waldenstrom's Macroglobulinemia; October 15-19, 2008; Stockholm, Sweden. Abstract 139.
33. Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia. 2009;23:153-161.
34. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079-4088. (Pubitemid 46211313)
35. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4070-4078. (Pubitemid 46211312)
36. Sacchi S, Pozzi S, Marcheselli R, et al. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. Cancer. 2007;110:121-128. (Pubitemid 46992032)
37. Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009;27:250-255.
38. Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood. 2008;112:4452-4457.
39. Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res. 2009;15:355-360.
40. Dunleavy K, Tay K, Wilson WH. Rituximab-associated neutropenia. Semin Hematol. 2010;47:180-186.
41. Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27:498-503.
42. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol. 2009;27:120-126.
43. Caravita T, Siniscalchi A, Tendas A, et al. High-dose therapy with autologous PBSC transplantation in the front-line treatment of Waldenstrom's macroglobulinemia. Bone Marrow Transplant. 2009;43:587-588.